• anti-obesity
  • One option is the use of anti-obesity medication the prescription of which has increased dramatically in recent years. (biomedcentral.com)
  • Despite this, little is known about the individual and GP practice factors that influence the prescription of anti-obesity medication. (biomedcentral.com)
  • Multi-level logistic regression analysis was used to investigate factors associated with the prescription of anti-obesity medication in Northern Ireland using a population primary care prescribing database (~1.5 million people aged 16+ years) during 2009/10. (biomedcentral.com)
  • While 25.0% of people are obese, only 1.3% (2.1% of females, 0.6% of males) received anti-obesity medication. (biomedcentral.com)
  • Prescribing of anti-obesity medication reflected obesity prevalence across urban/rural areas and deprivation. (biomedcentral.com)
  • There was an unexplained two-fold difference, between the 25th and 75th percentile, in the GP practice prescription of anti-obesity medication. (biomedcentral.com)
  • While the prevalence (and presumably the health consequences) of obesity worsens with age, younger females are more likely to be prescribed anti-obesity medication. (biomedcentral.com)
  • Educational material to improve the understanding of the role of anti-obesity medication, for patients and practitioners, is recommended. (biomedcentral.com)
  • In recent years, pharmacological treatment for obesity has been increasing against a backdrop of decreasing choice of available anti-obesity medications. (biomedcentral.com)
  • Orlistat (brand names Xenical/Alli) was first introduced in the UK and Europe in 1998 and is currently the main treatment option for those prescribed anti-obesity medication. (biomedcentral.com)
  • In Northern Ireland, during 2009/2010 orlistat accounted for approximately 80% of prescriptions for anti-obesity medication increasing to 99% following the withdrawal of sibutramine. (biomedcentral.com)
  • agents
  • Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity. (curehunter.com)